Market Newsdesk

CASTLE ROCK, Colo., Aug. 05, 2025 (GLOBE NEWSWIRE) — Riot Platforms, Inc. (NASDAQ: RIOT) (“Riot” or “the Company”), a Bitcoin-driven industry leader in the development of large-scale data centers for high performance compute and bitcoin mining applications, announces unaudited production and operations updates for July 2025.  

Bitcoin Production and Operations Updates for July 2025

1. Unaudited, estimated.
2. As of month-end.
3. Includes 3,300 in restricted bitcoin.
4. Average over the month.
5. Estimated power curtailment credits.
6. Estimated credits received from participation in ERCOT and MISO demand response programs.
7. Estimated. Inclusive of all transmission and distribution charges, fees, adders, and taxes. Net of Total Power Credits.
   

“Riot produced 484 bitcoin in July,” said Jason Les, CEO of Riot. “Historically, the summer months are more challenging for hash rate utilization, as we participate in ERCOT’s Four Coincident Peaks Program (“4CP”), voluntarily curtail as part of demand response programs, and operate in harsher conditions. Despite these factors, Riot increased production month over month and achieved an extremely low all-in power cost of $28/MWh, which is a testament to our operational improvements and our power management capabilities.

“Riot also made additional progress on our Data Center platform in July, closing on an additional 238 acres, located in proximity to our operations in Corsicana, TX. Collectively, Riot now owns 858 acres in Corsicana, giving us the flexibility to accommodate various data center designs and development plans which we are aggressively pursuing in order to be best positioned to fully utilize the 1.0 GW of power available at our Corsicana Facility.”

Human Resources Update

Riot is currently recruiting for positions across the Company. Join our team in building, expanding, and securing the Bitcoin network.

Open positions are available at: https://www.riotplatforms.com/careers.      

About Riot Platforms, Inc.   

Riot’s (NASDAQ: RIOT) vision is to be the world’s leading Bitcoin-driven infrastructure platform. Our mission is to positively impact the sectors, networks, and communities that we touch. We believe that the combination of an innovative spirit and strong community partnership allows the Company to achieve best-in-class execution and create successful outcomes.

Riot is a Bitcoin mining and digital infrastructure company focused on a vertically integrated strategy. The Company has Bitcoin mining operations in central Texas and Kentucky, and electrical engineering and fabrication operations in Denver, Colorado, and Houston, Texas.

For more information, visit www.riotplatforms.com.

Safe Harbor

Statements in this press release that are not historical facts are forward-looking statements that reflect management’s current expectations, assumptions, and estimates of future performance and economic conditions. Such statements rely on the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “anticipates,” “believes,” “plans,” “expects,” “intends,” “will,” “potential,” “hope,” similar expressions and their negatives are intended to identify forward-looking statements. These forward-looking statements may include, but are not limited to, statements relating to the Company’s development at its Corsicana Facility and the Company’s plans, projections, objectives, expectations, and intentions about future events and trends that it believes may affect the Company’s financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks and uncertainties, including, without limitation: risks related to the Company’s growth, the anticipated demand for AI/HPC uses, the feasibility of developing the Company’s power capacity for AI/HPC uses, competition in the markets in which the Company operates, market growth, the Company’s ability to innovate and expand into new markets, the Company’s ability to realize benefits from its implementation of new strategies into its business, estimates of Bitcoin production; our future hash rate growth (EH/s); the anticipated benefits, construction schedule, and costs associated with the development of our mining facilities in Texas, Kentucky and elsewhere; our expected schedule of new miner deliveries; our access to electrical power; the impact of weather events on our operations and results; our ability to successfully deploy new miners; the variance in our mining pool rewards may negatively impact our results of Bitcoin production; our megawatt capacity under development; risks related to the Company’s inability to realize the anticipated benefits from immersion cooling; the inability to integrate acquired businesses successfully, or such integration may take longer or be more difficult, time-consuming or costly to accomplish than anticipated; or the failure of the Company to otherwise realize anticipated efficiencies and strategic and financial benefits from our business strategies. Detailed information regarding the factors identified by the Company’s management which they believe may cause actual results to differ materially from those expressed or implied by such forward-looking statements in this press release may be found in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including the risks, uncertainties and other factors discussed under the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and the other filings the Company makes with the SEC, copies of which may be obtained from the SEC’s website, www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and the Company disclaims any intention or obligation to update or revise any such forward-looking statements to reflect events or circumstances that subsequently occur, or of which the Company hereafter becomes aware, except as required by law. Persons reading this press release are cautioned not to place undue reliance on such forward-looking statements.

Investor Contact:
Phil McPherson
303-794-2000 ext. 110
[email protected]

Media Contact:
Alexis Brock
303-794-2000 ext. 118
[email protected]

ATLANTA, Aug. 05, 2025 (GLOBE NEWSWIRE) — A shareholder class action lawsuit has been filed against PepGen Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information about PepGen’s business, operations, and prospects, including allegations that: (i) PGN-EDO51 was less effective and safe than Defendants had led investors to believe; (ii) the CONNECT2 study was deficient for purposes of U.S. Food and Drug Administration (“FDA”) approval; and (iii) as a result of all the foregoing, PepGen was likely to halt the CONNECT2 study, and PGN-EDO51’s clinical, regulatory, and commercial prospects were overstated.

If you purchased shares of PepGen between March 7, 2024 and March 3, 2025, and experienced a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at [email protected], by toll-free telephone at (888) 508-6832, or by visiting the firm’s website at www.holzerlaw.com/case/pepgen/ for more information.

The deadline to ask the court to be appointed lead plaintiff in the case is August 8, 2025.

Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, and 2023, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.

CONTACT:
Corey Holzer, Esq.
(888) 508-6832 (toll-free)
[email protected]

Istaroxime was added to currently available inotropes and vasopressors in the study – no new safety signals were identified and physiological improvements were consistent with istaroxime responses in previous trials

Cardiogenic shock is a severe presentation of heart failure and SCAI Stage C patients have low blood pressure and signs of organ damage due to low blood flow

These data provide the Company confidence to move forward with a global Phase 3 trial

WARRINGTON, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a diversified company with several divisions, including a cryptocurrency treasury strategy and two promising therapeutic pipelines for which the Company is actively seeking long-term development partners, has performed a planned interim analysis of the SEISMiC C Phase 2 study data evaluating istaroxime in SCAI Stage C cardiogenic shock which showed istaroxime had a similar profile to that seen in previous studies despite a greater severity of illness and being used in addition to currently available inotropes and vasopressors.

The SEISMiC C Study is a global trial including sites in the U.S., Europe and Latin America. It is placebo-controlled, double-blinded study with istaroxime being added to current standard of care, including inotropes or vasopressors in patients with more severe cardiogenic shock (SCAI stage C) than has been studied previously. The study follows the results of the SEISMIC B study where istaroxime was shown to improve blood pressure and hemodynamic variables such as cardiac output (the amount of blood pumped by the heart per minute), reduced filling pressures in the heart and improved signs of organ perfusion such as mixed venous oxygenation in patients with milder cardiogenic shock (SCAI stage B). This data is contributing to a very unique profile of istaroxime in acute decompensated heart failure across severity of illness. Inotropes and vasopressors agents are given to many patients in intensive care units in the USA every year and the results of the SEISMIC program may suggest potential advantages to istaroxime over existing therapies in efficacy and possibly safety. The SESIMIC C study was designed to assess the effects of istaroxime in patients with SCAI Stage C cardiogenic shock (i.e., more severe cardiogenic shock than patients enrolled in previous acute heart failure and cardiogenic shock studies in the past). Many patients in SESIMIC C were treated at the time of enrollment with vasopressors or inotropes and hence the SESIMIC C study is testing for the first time the safety and efficacy of istaroxime in more severe cardiogenic shock when istaroxime treatment is combined with other therapies for cardiogenic shock.

The interim analysis included the first 20 patients enrolled in the study. There were no new safety concerns identified, and no apparent excess arrhythmias in patients treated with istaroxime when given with standard of care therapies. The effects on hemodynamic and echocardiographic measures appeared to be consistent with results seen in previous istaroxime studies.

“The results of the SEISMIC C interim analysis are exciting,” said Jed Latkin, Chief Executive Officer of Windtree. “We believe these data will be instrumental in moving istaroxime to a global Phase 3 program in heart failure and cardiogenic shock. Steve Simonson, Chief Medical Officer added, “The interim data are consistent with the previous clinical study results seen in patients with AHF and less severe forms of cardiogenic shock. These data are encouraging for the potential of istaroxime to be effective across the spectrum of cardiogenic shock due to AHF with or without other inotropic or vasopressor drugs.”

About Istaroxime

Istaroxime is a first-in-class dual-mechanism therapy designed to improve both systolic and diastolic cardiac function. Istaroxime is a positive inotropic agent that increases myocardial contractility through inhibition of Na+/K+- ATPase with a complimentary mechanism that facilitates myocardial relaxation through activation of the SERCA2a calcium pump on the sarcoplasmic reticulum enhancing calcium reuptake from the cytoplasm. Data from multiple Phase 2 studies in patients with early cardiogenic shock or acute decompensated heart failure demonstrate that istaroxime infused intravenously can significantly improve cardiac function and blood pressure without increasing heart rate or the incidence of clinically significant cardiac rhythm disturbances.

About Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. is a diversified company with several divisions, including a cryptocurrency treasury strategy and two promising therapeutic pipelines for which the Company is actively seeking long-term development partners.

Forward Looking Statements

The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. Examples of such risks and uncertainties include, among other things: the success of the SEISMiC C Study, the ability to move istaroxime to a global Phase 3 program and risks related to the Company’s ability to manage costs and execute on its operational and budget plans. These and other risks are described in the Company’s periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact Information:

Eric Curtis
[email protected]

Cleveland, Aug. 05, 2025 (GLOBE NEWSWIRE) — CBIZ, Inc. (NYSE:CBZ), a leading national professional services advisor, today released its Employee Experience Guide, a new resource designed for companies looking to effectively attract, retain, and engage diverse employee populations spanning various generations and work arrangements. Going beyond compensation, this guide offers a distinct perspective on how companies can invest in their people from day one through retirement.

This guide emphasizes how a strong employee experience leads to better retention, higher productivity, and enhanced profitability. It also highlights the importance of not taking a one-size-fits-all approach when addressing the diverse needs of today’s workforce.

From attracting top talent with competitive total rewards packages, to leveraging recruiting technology and delivering a positive workplace experience, this guide gives organizations of all sizes insights to optimize every step of the employee journey.

An integrated approach to benefits, insurance, workforce development, and risk management is crucial to curate an effective employee experience. In recognition of this need, CBIZ developed this resource to provide uniquely holistic insights that encompass all of these key elements — helping businesses align their offerings to maximize impact. This guide is reflective of CBIZ’s integrated service model, which brings together advisors across a wide range of specialties to deliver comprehensive insights that impact.  

Technology also plays a big role. Tools like CBIZ’s Centrally HR help simplify payroll, onboarding, and compliance processes while eliminating errors and improving communication. The guide also helps companies rethink salary strategies, flexible benefits, retirement readiness, risk management, and best practices for offboarding.

“Employees are an organization’s most important asset and competitive differentiator,” said Polly Thomas, Chief Operating Officer of CBIZ Benefits and Insurance Services, Inc. “This guide will assist businesses in creating a bespoke experience for their people, leading to optimal team performance and results.”

This guide is now available for download and will give businesses the insights they need to build a stronger and more connected workforce. By focusing on what employees value most, companies can stay competitive in today’s world.

About CBIZ

CBIZ, Inc. (NYSE: CBZ) is a leading professional services advisor to middle market businesses and organizations nationwide. With unmatched industry knowledge and expertise in accounting, tax, advisory, benefits, insurance, and technology, CBIZ delivers forward-thinking insights and actionable solutions to help clients anticipate what’s next and discover new ways to accelerate growth. CBIZ has more than 10,000 team members across more than 160 locations in 22 major markets coast to coast. For more information, visit www.cbiz.com

ALBUQUERQUE, N.M., Aug. 05, 2025 (GLOBE NEWSWIRE) — ARRAY Technologies (NASDAQ: ARRY) (“ARRAY” or the “Company”), a leading global provider of solar tracking technology products, software and services, today announced it will supply trackers for a 200 megawatt (MWac) solar project that meet 100% of the domestic content Assigned Cost Percentage (ACP) under the U.S. Treasury Department’s latest guidance (Notice 2025-08) issued in January 2025. The domestic content trackers will be supplied to the Emerald Green Solar project in Indiana, which is being developed by ENGIE North America (ENGIE).

“This milestone underscores ARRAY’s commitment to American manufacturing and to helping our customers unlock the full value of tax credit incentives,” said Kevin G. Hostetler, chief executive officer at ARRAY. “Building on our 35-year legacy as an American manufacturer, ARRAY is proud to support reshoring of supply chains and job creation in the communities where we operate. ARRAY is a leader in delivering domestic content clean energy solutions that benefit our customers and the regions they serve.”

This project represents ARRAY’s first full-site deployment of its 100% domestic content tracker solution, which enables developers to qualify for the maximum 28.7% ACP, which includes the 9.4% production ACP available exclusively for projects using trackers with only domestic content manufactured product components.

“ENGIE is thrilled that domestically produced solar trackers will be deployed at our Emerald Green Solar project in Howard County, Indiana. The ability to work with a U.S. manufacturer of qualified domestic content components for this 200 MWac project supports ENGIE’s commitment to delivering local economic benefits in the states and communities where we operate as well as in the wider American economy,” said David Carroll, Chief Renewables Officer and Senior Vice President at ENGIE North America. “The fact that the steel used in ENGIE’s largest energy project in Indiana will include torque tube and steel rolled locally in the state and installed by some of the more than 250 construction workers that will build the project really reflects the local nature of renewable energy production in the U.S.”

The project, located about an hour north of Indianapolis, Indiana, will be built entirely with domestic content ARRAY OmniTrack™ trackers. To validate full compliance with federal guidelines, ARRAY partnered with a third-party tax and advisory firm to analyze its manufacturing processes and supply chain.

Deliveries of the trackers are expected to begin in Q3 2025.

About ARRAY

ARRAY Technologies (NASDAQ: ARRY) is a leading global provider of solar tracking technology to utility-scale and distributed generation customers who construct, develop, and operate solar PV sites. With solutions engineered to withstand the harshest weather conditions, ARRAY’s high-quality solar trackers, software platforms and field services combine to maximize energy production and deliver value to our customers for the entire lifecycle of a project. Founded and headquartered in the United States, ARRAY is rooted in manufacturing and driven by technology – relying on its domestic manufacturing, diversified global supply chain, and customer-centric approach to design, deliver, commission, train, and support solar energy deployment around the world. For more news and information on ARRAY, please visit arraytechinc.com.

Forward Looking Statement

This press release contains forward-looking statements that are inherently speculative in nature and involve a number of risks, uncertainties, and assumptions that could cause actual results to differ materially from those anticipated or implied by such statements. These statements are made under the “Safe Harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements by terms or words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates” and similar expressions. These forward-looking statements are not historical facts but are based on the Company’s current expectations, projections, and assumptions about its business, operations, and other factors. These statements are only predictions based on current expectations and, therefore, are not guarantees of future performance. The Company’s forward-looking statements involve significant risks, uncertainties, and assumptions, including, without limitation, any increase in interest rates, or a reduction in the availability of tax equity or project debt capital in the global financial markets; unexpected changes or new policies and regulations related to the electric utility industry; the reduction, elimination or expiration, or our failure to optimize the benefits of government incentives; changes to laws and regulations, or the guidance thereto, including changes to tax laws and regulations, that are applied adversely to ARRAY or ENGIE; and significant changes in the cost of raw materials. These factors may hinder the Company’s ability to meet its expectations and could lead to actual results materially differing from those stated. Additionally, disruptions to transportation and logistics, including increases in shipping costs; defects or performance problems in the Company’s products; and the availability of in-demand components like high voltage breakers as well as various policies related to the permitting and interconnection costs of solar plants may impact the anticipated benefits of the project or the timing of those benefits. Forward-looking statements should be evaluated together with the risks and uncertainties that affect our business and operations, particularly those described in more detail in the Company’s most recent Annual Report on Form 10-K, its most recent Quarterly Report on Form 10-Q, and its other documents on file with the SEC, which are available on ARRAY’s website, www.arraytechinc.com. The Company assumes no obligation to update or revise any forward-looking statements, except as required by law, even if new information becomes available or future events occur that may materially alter the anticipated outcome.

Media Contact

Nicole Stewart
505-589-8257
[email protected]

Investor Relations

Investor Relations
[email protected]

DALLAS, Aug. 05, 2025 (GLOBE NEWSWIRE) — The average starting salary for physicians is $403,000, with orthopedic surgeons at the high end of the starting salary scale at $576,000 and pediatricians at the low end at $258,000, according to an annual report from AMN Healthcare’s Physician Solutions division (formerly known as Merritt Hawkins).

The 2025 Review of Physician and Advanced Practitioner Recruiting Incentives, now in its 32^nd year, tracks starting salaries and other incentives offered by hospitals and medical groups to physicians, nurse practitioners (NPs) and other advanced practice professionals. Specialists are offered the top starting salaries among physicians, according to the report. After orthopedic surgeons, gastroenterologists are offered the highest average starting salary at $552,000, followed by urologists at $521,000, radiologists at $500,000 and hematologists/oncologists at $490,000.

“Demand for specialists is particularly strong and is being driven by the rapid growth of the nation’s senior citizen population,” said Leah Grant, president of AMN Healthcare Physician Solutions. “While demand is growing, many specialists are in short supply, resulting in high starting salary offers.”

Primary care physicians are offered significantly lower starting salaries than specialists. Family medicine physicians are offered an average starting salary of $275,000, less than half that of orthopedic surgeons, while internal medicine physicians are offered an average of $290,000, and pediatricians $258,000.

Starting salaries for most physicians tracked in the report have increased year over year. The average starting salary for otolaryngologists saw the largest year-over-year gain, growing from $358,000 last year to $487,000 this year, a 36% increase. The average starting salary for cardiologists grew from $396,000 last year to $470,000 this year, an increase of 19%, while the average starting salary for hematologists/oncologists grew from $444,000 last year to $490,000 this year, a 10% increase.

Starting Salaries for NPs Increasing

While NPs are offered lower starting salaries than physicians, salary offers to NPs are also increasing according to the report. The average starting salary offer for NPs is $180,000, a 9.6% increase from $164,000 in 2024.

“NPs are in rapidly growing demand as physician shortages persist,” Grant said. “Without them, access to healthcare would be even more problematic, particularly in rural and other underserved areas.”

Specialties in the Most Demand

Each year, AMN Healthcare’s report calculates which types of physicians are in the most demand by comparing the number of job openings in a given specialty to the number of physicians in that specialty. By this calculation, the five types of physicians in most demand are hematologists/oncologists, gastroenterologists, endocrinologists, and radiologists. However, in an era of physician shortages, job prospects are abundant across medical specialties, according to Grant.

“While certain types of physicians are in particular demand, there are job openings for most physicians regardless of specialty,” Grant said. “In today’s market, there is virtually no such thing as an unemployed physician.”

Signing Bonuses, Relocation and Continuing Medical Education

In addition to starting salaries, physicians and NPs often are offered signing bonuses, relocation allowances and continuing medical education (CME) allowances. The average signing bonus for physicians tracked in the report is $38,315, up 23% from $31,103 last year, while the average relocation allowance for physicians is $12,619, up 12% from $11,284 last year. The average CME allowance for physicians is $4,073, up 3% from $3,969 last year.

Combined, the average signing bonus, relocation and CME allowance offered to physicians is $58,854, which is in addition to an average starting salary of $403,00 for all physicians tracked in the report. Most physician and NP employment contracts also offer benefits like health insurance, malpractice insurance and retirement/401k plans.

AMN Healthcare’s 2025 Review of Physician and Advanced Practitioner Recruiting Incentives is based on a representative sample of the 1,420 search engagements the company conducted from April 1, 2024, to March 31, 2025, and includes data on starting salaries and other incentives offered by the company’s clients to physicians and advanced practice professionals nationwide. A copy of the report can be accessed at https://online.flippingbook.com/view/72701021/

About AMN Healthcare
 
 

AMN Healthcare is the leader and innovator in total talent solutions for healthcare, bringing together the people, processes and technology to deliver better care. Through a steadfast partnership approach, we solve the most pressing workforce challenges to enable better clinical outcomes and access to care. In 2024 our healthcare professionals reached nearly 15 million patients at more than 2,100 healthcare systems, including 87 percent of the top healthcare systems nationwide. We provide a comprehensive network of quality healthcare professionals and deliver a fully integrated and customizable suite of workforce technologies. For more information, visit www.amnhealthcare.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/668562cc-c06f-49a8-9190-f9686efe0e1c

Selangor, Malaysia, Aug. 05, 2025 (GLOBE NEWSWIRE) — Empro Group Inc. (the “Company”, “Empro”, or “EMPG”), a rising beauty and personal care brand headquartered in Malaysia, is proud to confirm its successful listing on the Nasdaq Capital Market under the ticker symbol “EMPG” and the completion of its previously announced initial public offering (IPO) of ordinary shares. Empro’s ordinary shares commenced trading on July 2, 2025, marking a historic milestone as the first beauty brand from Malaysia to be publicly listed in the United States.

The IPO was upsized from $5.0 million to $5.5 million, with 1,375,000 ordinary shares priced at $4.00 per share. The underwriter for the IPO exercised its over-allotment option in full as a result of partial exercises on each of July 29, 2025 and July 31, 2025, purchasing an aggregate of 206,250 additional ordinary shares at the $4.00 public offering price. In total, the IPO generated gross proceeds of approximately $6.325 million, before deducting underwriting discounts and offering expenses.

The offering was conducted on a firm commitment basis, with R.F. Lafferty & Co., Inc. serving as the sole underwriter. ARC Group acted as the sole financial advisor to the Company.

“This listing is a proud moment for Empro. Being the first Malaysian beauty brand to be listed on Nasdaq is a testament to the strength of our products, the resilience of our team, and the global potential of Southeast Asian brands,” said Mr. Yeoh Chee Wei, Empro’s Chairman and CEO. “We would like to extend our appreciation to all of our stakeholders, partners and advisors, including ARC Group, whose strategic guidance and unwavering support were instrumental in making this IPO a success.”

Evolving from its roots in eyebrow embroidery, Empro has grown into a trusted name across three pillars: cosmetics, skincare, and healthcare. The Company believes its Nasdaq listing will unlock exciting new growth opportunities, strengthen its brand visibility internationally, and position it to expand its footprint across global markets.

“We are thrilled to join the growing family of Southeast Asian companies listed in the United States,” Mr. Yeoh added. “This listing marks a new chapter in our journey to bring innovative, high-quality beauty and personal care products from Malaysia to the world, including our recently launched flagship skincare product, SpaceLift.”

About Empro Group Inc.

Empro Group Inc. is a rising beauty and personal care brand headquartered in Malaysia. Evolving from its origins in Malaysia’s eyebrow embroidery space, Empro Group Inc. has grown into a trusted name across three core pillars: cosmetics, skincare, and healthcare. With a growing presence across Southeast Asia and Europe, Empro Group Inc. remains dedicated to offering accessible, quality self-care solutions while staying true to its humble beginnings. For more information please visit: https://www.empro.my/.

Forward-Looking Statement

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, the Company’s statements regarding the expected trading of its Ordinary Shares on the Nasdaq Capital Market and the closing of the Offering. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These forward-looking statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and the completion of the initial public offering on the anticipated terms or at all, and other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

Investor Relations

Visit emproinc.co
Or contact us at [email protected]